Veraguth P
Schweiz Med Wochenschr. 1977 Jul 16;107(28):997-1002.
The role of radiotherapy in the treatment of mammary carcinoma is reviewed. The indication for postoperative radiotherapy in cases of primary tumors T2 and T3, particularly in the presence of metastatic lymph nodes (N1), is still given. For stage 1 (T1/T2 N0), postoperative radiotherapy may be omitted or can be limited to the lymphatic area which has not been surgically explored. Pre-operative radiotherapy for the more advanced stage (T3/T4 and N2) has proven more effective than postoperative irradiation. Radiotherapy as an exclusive procedure in the sense of a curative, non-mutilating treatment for small breast cancers(T1/T2 NO) provides, if correctly administered, the same 5- and 10-year survival rate at surgical amputation. The arguments against the use of radiotherapy (lymphopenia, diminished immunological reactions, frequency of hematogenic metastases) are discussed.
本文综述了放射疗法在乳腺癌治疗中的作用。对于原发性肿瘤为T2和T3期的病例，尤其是存在转移性淋巴结（N1）时，术后放疗的指征仍然存在。对于1期（T1/T2 N0），术后放疗可以省略，或者可以局限于未进行手术探查的淋巴区域。对于更晚期（T3/T4和N2）的术前放疗已被证明比术后放疗更有效。对于小乳腺癌（T1/T2 N0），放射疗法作为一种根治性、非致残性的唯一治疗方法，如果正确应用，在手术切除时可提供相同的5年和10年生存率。文中讨论了反对使用放射疗法的理由（淋巴细胞减少、免疫反应减弱、血行转移频率）。
